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Objective: Heart–lung transplantation for patients with pulmonary atresia and ventricular septal defect is chal-
lenging. The aim of the study was to present a single-center experience with heart–lung transplantation in this
difficult group of patients.
Methods: A retrospective review identified 9 patients aged 4.1 to 45.6 years (median, 25.4 years) with pulmonary
atresia and ventricular septal defect who underwent heart–lung transplantation. Four (44.4%) patients had pre-
vious heart operations: 3 of them had palliative procedures (systemic-to-pulmonary shunts), and 1 had multistage
correction. A standard transplantation method was used, with the exception of 1 patient with heterotaxy syndrome
who underwent a modified operation. Major aortopulmonary collateral arteries were controlled by using various
techniques.
Results: Follow-up ranged between 2 days and 12.6 years (median, 1.2 years). The hospital mortality rate was
22.2% (n¼ 2). In the late postoperative period, 3 patients died. The survival curve was similar to that of patients
with other diagnoses undergoing heart–lung transplantation. The median length of intensive care unit stay was 58
days (range, 22–82 days), and the median length of hospital stay was 83 days (range, 35–136 days). The most
common early complication was bleeding requiring re-exploration. In all cases the bleeding was proved to be
from collateral vessels.
Conclusions: Heart–lung transplantation in patients with pulmonary atresia and ventricular septal defect requires
carefully planned and meticulously performed surgical intervention. This management should be taken into con-
sideration as a future option if the specific anatomy is uncorrectable in early childhood, and the palliative proce-
dures should be avoided.The most common indication for heart–lung transplantation
(HLTx) today is congenital heart disease.1 Although com-
bined heart and lung transplantation is a conceptually simple
procedure, requiring only 3 relatively easy anastomoses, for
some congenital heart defects, this operation might be chal-
lenging. Patients with pulmonary atresia with ventricular
septal defect (PAþVSD; tetralogy of Fallot with pulmonary
atresia) present technical difficulties because of numerous
collateral vessels, adhesions caused by previous operations,
and often coexistence of unusual anatomy and are usually in
worse condition than other transplant recipients (usually
with renal and hepatic dysfunction). These patients are chal-
lenging at every stage of clinical management.
The aim of this retrospective study was to present a single-
center experience with HLTx in patients with PAþVSD to
analyze the methods used in management and the problems
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MATERIALS AND METHODS
Between February 1983 and March 2008, 73 patients underwent HLTx
at the Department of Cardiac Surgery, Klinikum Grosshadern, Ludwig
Maximilians University, Munich, Germany. A retrospective review identi-
fied 9 patients, 4 (44.4%) female and 5 (55.6%) male, who underwent
HLTx for PAþVSD.
Patient age at the time of transplantation ranged from 4.1 to 45.6 years
(mean  standard deviation, 27.4  15.3 years; median, 25.4 years). All the
children (n¼ 2) and 86% of the adult patients (n¼ 6) were underweight (adult
body mass index: range, 17.0–29.9 kg/m2; median, 20.1 kg/m2). All patients
were symptomatic because of effort intolerance and dyspnea of various de-
grees and had New York Heart Association class III to IV symptoms. Cyanosis
was evident, and clubbing was noted. The median arterial oxygen saturation
was 73.0% (range, 60%–80%), and the median hemoglobin value was
20.8 g/dL (range, 14.5–24.0 g/dL). Six (66.7%) patients required continuous
supplemental oxygen, and in 3 of them, regular phlebotomies were performed
for polycythemia to decrease the hematocrit value. In 4 (44.4%) patients mul-
tiple supraventricular and ventricular arrhythmias occurred, and 2 of them sur-
vived episodes of ventricular fibrillation, from which they were resuscitated
without sequel. Four (44.4%) patients had chronic renal insufficiency in
a compensatory phase, 2 (22.2%) had congenital kidney malformation, 3
(33.3%) had hepatic dysfunction caused by prolonged congestion, 1 survived
endocarditis, and 1 underwent phlebothrombosis of the left popliteal vein. Be-
cause of progressive disability, poor life expectancy, and absence of alternative
therapeutic options, the patients were put on the HLTx waiting list.
All patients were subjected to cardiac catheterization and angiography, the
latter including multiple injections into the thoracic aorta and selective injec-
tions into the large collateral arteries. All patients had major aortopulmonaryrgery c September 2009
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CMV ¼ cytomegalovirus
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HLTX ¼ heart–lung transplantation
MAPCA ¼ major aortopulmonary collateral artery
PAþVSD ¼ pulmonary atresia with ventricular
septal defect
collateral arteries (MAPCAs; Figure 1). Four (44.4%) patients had previous
heart operations: 3 of them underwent palliative procedures (systemic-to-
pulmonary shunts), and 1 patient (no. 5) had multistage correction (right
ventricular outflow tract reconstruction with atrial and ventricular septal
defect closure and MAPCA ligation). One patient (no. 3) underwent dilata-
tion of a stenotic MAPCA with stent implantation. Details of previous
procedures, as well as preoperative characteristics, are presented in Table 1.
For donor cardiac preservation, Bretschneider cardioplegic solution was
used until 1994, when it was replaced by University of Wisconsin solution.
Pulmonary procurement was performed with Euro–Collins solution until
1996, and thereafter it was replaced with Perfadex solution. A median ster-
notomy incision was used in all recipients with no history of previous ster-
notomies. In the remainder a bilateral transverse thoracotomy (‘‘clamshell
incision’’) was done. Collateral vessels, as many as possible, were identified
before institution of cardiopulmonary bypass (CPB) and ligated or oversewn
immediately after starting CPB. In 5 patients it was necessary to institute pro-
found hypothermia and decrease the perfusion rate to control the bleeding
from the collateral arteries. Extensive and large collateral arteries were
controlled after clamping of the entire hilum. MAPCAs arising from the
descending aorta were dissected by means of incision of the posterior peri-
cardium. Once the hemostasis was achieved, the donor heart–lung bloc
was implanted according to the technique described by Reitz and associates.2
In patient 9, who had heterotaxy syndrome, dextrocardia, situs inversus
atrialis, single ventricle (unbalanced atrioventricular canal with hypoplastic
left ventricle), and agenesis of the right superior vena cava with persistence
of the left superior vena cava, a modified implantation technique was used.
The inferior and superior venae cavae drained to the left-sided recipient
atrium (atrial inversion). After removal of the recipient heart, the remnants
of the left-sided right atrium were sewn together and anastomosed with the
donor right atrium, with the rotation of the donor heart in a clockwise direc-
tion in the long axis of about 60.
Immunosuppressive treatment consisted of a combination of cyclosporin
A, azathioprine, and steroids. This regimen was applied until 1995, when
cyclosporine was replaced with tacrolimus. In 1997, azathioprine was
replaced with mycophenolate mofetil. Methylprednisone was initiated
intraoperatively with a 500-mg intravenous bolus and tapered down to
0.1 mg$ kg1 $d1 within 6 months. Dosing of cyclosporine A, tacrolimus,
and mycophenolate mofetil was titrated to maintain a serum concentration
of between 250 and 300 ng/mL, 10 and 15 ng/mL, and 2 and 4 mg/mL, re-
spectively. Azathioprine was administered in a daily dose of 0 to 2 mg/kg to
maintain a white blood cell count of greater than 4000 cells/mL.
Antibacterial prophylaxis included imipenem for the first 48 hours after
HLTx. Antifungal prophylaxis with oral nystatin and aerosolized amphoter-
icin B was administered within the 7 first postoperative days. Cytomegalo-
virus (CMV) prophylaxis with ganciclovir was used in any CMV-positive
recipient and in any CMV-negative recipient receiving an allograft from
a CMV-positive donor. Pneumocystis carinii prophylaxis consisted of
trimethoprim–sulfamethoxazole.
During follow-up, patients were reviewed at regular intervals: once a week
for the first 2 months and then gradually extended to 3-month intervals.
Statistical analysis was carried out by means of descriptive statistics and
the Mann–Whitney test for continuous variables. Patient survival was esti-The Journal of Thoracic and Cmated by using the Kaplan–Meier method. Data are presented as mean
values with standard deviations or median values with ranges.
RESULTS
Donors for the recipients reported here were found within
a median waiting period of 60 days (range, 38–458 days).
FIGURE 1. Collateral vessels in patient 8: A, posterior aspect of the aorta
showing MAPCAs (M) from the aortic arch and Waterstone shunt (W); B,
anterior aspect of the aorta showing 3 MAPCAs (3M) from the descending
aorta.ardiovascular Surgery c Volume 138, Number 3 739
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Patient
no.
Age
(y)
Weight
(kg)/BMI
Associated
features
Pulmonary
arteries MAPCAs
Previous operations/
catheter interventions
Cardiac Noncardiac MPA/Confl LPA/RPA No. Origin Age Operation/approach
1 25.4 51.0/17.0 Aberrant right
subclavian artery
0/0 0/0 1 AoArch 0
2 8.2 18.0/10.6 0/1 H/H 1 Tr Br-ceph 2 y LBTS/LTh
4 y Waterstone/S
3 25.3 106.0/29.9 RAA Renal insufficiency 0/0 0/0 2 AoDesc 23 y MAPCA–stent
implantationAoDesc
4 4.1 13.5/13.5 Left kidney
agenesis, right kidney
dysplasia
1/1 H/H ? 2 mo MPA–AoAsc
(end-to-side)/S
3.7 y Aoasc–LPA shunt/S
3.8 y RPA–stent implantation
3.8 y LBTS/LTh
5 17.7 51.0/18.1 Arrhythmia Hepatic dysfunction
left kidney cyst
0/1 H/H 2 AoDesc 2 mo RV–PA conduit/S
AoDesc
1.3 y
VSD, ASD closure,
new conduit,
MAPCA–ligation/S
8.5 y New conduit/S
6 36.0 54.0/17.6 RAA Phlebothrombosis 0/1 H/H 1 AoDesc 0
7 45.3 55.0/20.2 RAA Hepatic dysfunction
renal insufficiency
1/1 H/H 1 AoDesc 0
Endocarditis
Arrhythmia
8 39.4 58.0/20.1 Arrhythmia Hepatic dysfunction
renal insufficiency
0/0 0/H 4 AoArch 6.5 y Waterstone/RTh
AoDesc
AoDesc
AoDesc
9 45.6 58.0/20.1 SV (RV), Hx, Dx,
CAVC, LCVS, situs
inversus atrialis;
arrhythmia
Renal insufficiency 0/0 0/0 4 RSCA 0
AoArch
AoDesc
AoDesc
MAPCA, Major aortopulmonary collateral artery; BMI, body mass index; MPA, main pulmonary artery; Confl, pulmonary arteries confluence; LPA, left pulmonary artery; RPA,
right pulmonary artery; AoArch, aortic arch; H, hypoplastic; Tr Br-ceph, truncus brachiocephalicus; LBTS, left Blalock–Taussig shunt; LTh, left posterolateral thoracotomy; S,
sternotomy; RAA, right aortic arch; AoDesc, descending aorta; AoAsc, ascending aorta; RV–PA, right ventricle–pulmonary artery; VSD, ventricular septal defect; ASD, atrial septal
defect; RTh, right posterolateral thoracotomy; SV, single ventricle; RV, right ventricle; Hx, heterotaxy syndrome; Dx, dextrocardia; CAVC, complete atrioventricular canal; LSVC,
left superior vena cava; RSCA, right subclavian artery.The patients with previous operations (n ¼ 4) were younger
at the time of HLTx (median, 12.9 years; range, 4.1–39.4
years) than patients with no history of thoracic surgery (me-
dian, 35.9 years; range, 25.3–45.6 years), but the difference
did not reach statistical significance (P ¼ .086).
During the HLTx, the median CPB time was 350 minutes
(range, 199–625 minutes), and the median duration of aortic
crossclamping was 198.5 minutes (range, 151–321 minutes).
Follow-up ranged between 2 days and 12.6 years (median,
1.2 years). The immediate postoperative course was compli-
cated in 8 (88.9%) patients by excessive bleeding, which re-
quired rethoracotomy within the first 24 hours. In 6 (75%) of
them, the re-exploration caused by bleeding was done more
than once, and in 3 (37.5%) patients it was done more than
twice. In all cases bleeding was proved to be from the collat-
eral vessels in the posterior mediastinum or in the chest wall.
In the early postoperative period, these 8 patients required
massive blood transfusions and received 8 to 43 packed red740 The Journal of Thoracic and Cardiovascular Sublood cell units (median, 24.5 units). Apart from bleeding,
the most common postoperative complication was respira-
tory failure requiring prolonged mechanical ventilation
(defined as assisted ventilation for>72 hours or reintuba-
tion), which occurred in 6 (85.7%) early survivors (Table 2).
The median ventilatory support time was 36 days (range,
18–77 days). Five (55.6%) patients required tracheostomy.
Acute renal failure (which required dialysis), was noticed
in 5 (55.6%) patients. The median length of intensive care
unit stay among survivors was 58 days (range, 22–82 days),
and the median length of hospital stay was 83 days (range,
35–136 days). Six early survivors among the transplant re-
cipients were discharged from the hospital (1 patient is still
in the intensive care unit). The most common late complica-
tion was bronchiolitis obliterans in 2 (28.6%) patients,
chronic renal failure in 2 (28.6%) patients, and polyneurop-
athy in 2 (28.6%) patients. All survivors after discharge were
in New York Heart Association class I or II.rgery c September 2009
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postoperative period, 3 patients died. The Kaplan–Meier
survival curve of the entire group is presented on Figure 2.
Early and late morbidity, as well as causes for early and
late mortality, are shown in Table 2.
DISCUSSION
PAþVSD embryologically and anatomically is an extreme
form of tetralogy of Fallot. This anomaly presents in a wide
spectrum of severity according to the development of pul-
monary arteries and occurrence of aortopulmonary collateral
vessels.
The natural history of patients with PAþVSD is very poor.
The probability of survival to the first birthday is only 60%.3
The most mild anatomic form (normally developed branch
pulmonary arteries with duct-dependent pulmonary flow
without MAPCAs) manifests very early, with profound cy-
anosis when the ductus closes. The children with the most
severe anatomic form (absent main and branch pulmonary
arteries with MAPCA-dependent pulmonary flow without
ductus arteriosus) are usually free of symptoms for a long
time. Ten percent of children might have the first diagnosis
after the 10th year of life and maintain an excellent func-
tional status into their teenage years or young adulthood.3
TABLE 2. Complications and causes of deaths
No. (%)
In-hospital complications
Early deaths 2 (22.2)
Case 5—graft dysfunction (myocardial infarction)
Case 7—multiorgan failure
Early morbidity among early survivors
Prolonged mechanical ventilation (>72 h) 6 (85.7)
Acute renal insufficiency 5 (71.4)
Infection, pulmonary
Candida species 4 (57.1)
Aspergillus species 2 (28.6)
Cytomegalovirus 1 (14.3)
Infection, generalized 2 (28.6)
Lung acute rejection 3 (42.9)
Tracheal stenosis (stent implantation) 1 (14.3)
V. jugularis interna thrombosis (stent implantation) 1 (14.3)
Phrenic nerve injury 1 (14.3)
Late complications
Late deaths 3 (42.9)
Case 1—pulmonary infection/bronchiolitis obliterans
Case 2—bronchiolitis obliterans
Case 3—renal insufficiency
Late morbidity among early survivors
Bronchiolitis obliterans 2 (28.6)
Chronic renal insufficiency 2 (28.6)
Polyneuropathy 2 (28.6)
Tracheal stenosis (stent implantation) 1 (14.3)
Aorta ascendens aneurysm 1 (14.3)The Journal of Thoracic and CThe gradual deterioration of oxygen saturation and reduction
of effort tolerance are characteristic for adult cyanotic
patients.4-6
Although pediatric cardiac surgery evolved significantly
during the past decades, the strategy of surgical treatment
for PAþVSD remains controversial. Definitive correction
in early infancy can be applied without controversy in
duct-dependent forms of the anomaly.7-11 In more severe an-
atomic forms, most authors advocate multistage repair.12-14
The association between the right ventricle and pulmonary
circulation should be established as early as possible to en-
sure more normal development of alveolar number and the
total cross-sectional area of pulmonary capillaries.10,12,13,15
Younger children (<5 years of age) have the potential for
development of the pulmonary tree.12 Older children, teen-
agers, or adult patients with PAþVSD have fewer genera-
tions of bronchoalveolar and pulmonary vascular tree,15
and surgical treatment in such patients is not only challeng-
ing, but also, the results are worse than the natural history of
the disease.12,14 The only treatment option that can improve
the prognosis for these patients is HLTx.
Palliative shunt procedures in children with PAþVSD are
today more and more rarely performed. Dissection and su-
ture lines are well-known causes of stenosis and distortion
of the pulmonary arteries, impairing their future develop-
ment. MAPCAs, which are muscular arteries until they pen-
etrate the lung parenchyma (where they have an elastic
media, like pulmonary arteries), have the tendency to de-
velop severe stenoses.12 The junction between muscular
and elastic segments (especially adjacent to bifurcation) is
usually marked by an intimal hyperplasia that also partially
obstructs the vessel. Beyond this stenosis, the vessel usually
shows a sinusoidal dilation.15 The natural stenoses of
FIGURE 2. Actuarial survival after heart–lung transplantation (HLTx) in
patients with pulmonary atresia and ventricular septal defect (PAþVSD) in
comparison with the whole group of HLTx recipients in our institution (All).ardiovascular Surgery c Volume 138, Number 3 741
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rapid development of obstructive disease. The surgically
created systemic-to-pulmonary artery shunts do not have
these protective changes and usually cause earlier develop-
ment of histologic changes in the pulmonary vessels.15
Among our patients, we observed the tendency to be youn-
ger at the time of HLTx if the patient had undergone previ-
ous shunt procedures. We advocate that in patients with
PAþVSD, the shunt procedures (as the only and long-term
palliation) should be abandoned because they might worsen
the natural history of the anomaly. If the specific anatomy is
uncorrectable in early periods of life, multiple palliative
procedures should be avoided because they not only do
not improve the prognosis for the patient3 but also increase
the risk of bleeding complications at HLTx.16
The most frequent postoperative complication in our pa-
tients was bleeding, which required re-exploration. Dense
adhesions after previous operations, longstanding cyanosis,
hepatic dysfunction, routine prophylactic preoperative anti-
coagulation, long CPB time, and massive transfusion are all
factors that can contribute to bleeding complications. The
previous history of thoracic surgery is a well-known risk fac-
tor for hospital death after HLTx17 and is even considered as
a relative contraindication for HLTx by some authors.18 Ad-
hesions caused by previous operations are associated with
the presence of small vessels from the chest wall and usually
are successfully controlled through the bilateral clamshell
thoracotomy.19 In our opinion the bleeding complications
are first of all associated with ineffective control of the
true collateral vessels (MAPCAs). Meticulous hemostasis
requires a precise preoperative definition of their origin,
course, size, and number. It is crucially important for the sur-
geon to know the specific patient’s anatomy before the oper-
ation and understand the relationship of the collateral vessels
to other mediastinal structures.
MAPCAs embryologically are the persistence of connec-
tions between the aorta and the pulmonary vasculature.12,20
MAPCAs most commonly arise from the proximal descend-
ing aorta at the level of the tracheal carina (T4). Almost all
arise 1 or 2 vertebral spaces above or below this level.12
About 55% patients with PAþVSD have more than 2 MAP-
CAs.3 Nevertheless, collateral vessels are highly variable in
their size, number, course, origin, and arborization, and all
available diagnostic methods should be used and carefully
studied before embarking on the procedure.
The ligation or at least identification of collateral vessels
should be performed, if possible, before the establishment
of CPB. This strategy can not only shorten the CPB time,
which per se is a risk factor for the postoperative bleeding,
but also diminish the runoff through the collateral arteries
to the pulmonary circulation and the danger of longstanding
systemic hypoperfusion. Unfortunately, the majority of col-
lateral vessels arise in the subcarinal region and require CPB
to be reached. The use of moderate or deep hypothermia can742 The Journal of Thoracic and Cardiovascular Surhelp to dry the operative field through the opportunity of
flow decreasing in the cardiopulmonary circulation. Apart
from this measure, we also applied a maneuver of clamping
the whole lung hilum or temporarily closing the pulmonary
veins (tourniquets) to decrease the bleeding and approach
the collaterals. The problem of collateral vessel control can
be addressed by use of double aortic cannulation (ascending
aorta and distal descending aorta) and exclusion of the prox-
imal descending aorta from perfusion during hemostasis.21
Nowadays some of the large and difficult to reach MAPCAs
can be controlled by using transcatheter techniques at the be-
ginning of the HLTx (hybrid procedure). Perfect hemostasis
is necessary to achieve before graft implantation because the
region of bleeding is inaccessible at later time points. The
proper time coordination between the donor and recipient
team has a very important role in this specific group of
patients. Sometimes meticulous hemostasis requires a lot
of time, and the donor team should even wait for the recip-
ient team to decrease the graft ischemic time to a minimum.
The long graft ischemic time is a well-known cause of early
graft failure, which is the most important reason for 30-day
mortality after HLTx.1
Our results are encouraging because all survivors benefited
from HLTx, both in terms of survival and quality of life. The
overall mortality rate observed in the study series is compara-
ble with that of the patients with other indications for HLTx
operated on in our institution22 and with that noted by
others.1,23 The results of our study indicate that HLTx in pa-
tients with PAþVSD requires carefully planned and meticu-
lously performed surgical intervention. Nowadays HLTx is
an established method of treatment for patients with end-stage
cardiopulmonary disease. This management should be taken
into consideration as a future option for children with
PAþVSD if the specific anatomy is uncorrectable in early pe-
riods of life. The multiple palliative procedures should be then
avoided because they can worsen prognosis for the patient.
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